文献速递泌尿男性生殖肿瘤

开发并验证人工智能数字病理学生物标志物预测高危前列腺癌男性长期激素治疗与放疗获益:跨多项III期试验

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials.
PubMed 文献 · J Clin Oncol · 2025-04-16

研究利用六项NRG肿瘤学III期随机放疗试验的数字化前列腺活检图像和临床数据,训练多模态人工智能(MMAI)衍生预测生物标志物,用于预测长期对比短期雄激素剥夺治疗(ADT)的远处转移(DM)差异获益,并在第七项RTOG 9202试验(N=1,192)中验证。验证队列中位随访17.2年,长期ADT显著改善DM(26%降至17%;sHR 0.64,P<.001);MMAI阳性男性(n=785)长期ADT较短期ADT降低DM(sHR 0.55,P<.001),MMAI阴性男性(n=407)无治疗获益(sHR 1.06,P=.84);生物标志物与治疗交互作用显著(P=.04)。

要点

  • MMAI生物标志物可预测高危前列腺癌放疗联合ADT的远处转移差异获益,交互作用P=.04。
  • MMAI阳性男性长期ADT较短期ADT降低DM(sHR 0.55,95%CI 0.41-0.73,P<.001)。
  • MMAI阴性男性长期ADT与短期ADT无显著DM获益差异(sHR 1.06,95%CI 0.61-1.84,P=.84)。

核心结论

  • MMAI模型是首个经验证的预测生物标志物,用于指导局部/局部晚期前列腺癌放疗中的ADT持续时间;约三分之一高危前列腺癌男性可能安全地免于额外24个月ADT及其相关疾病负担。

研究设计与样本

  • 利用六项NRG肿瘤学III期随机放疗试验的预处理数字化前列腺活检图像和临床数据(年龄、前列腺特异性抗原、Gleason评分和T分期),训练MMAI衍生预测生物标志物,预测长期对比短期ADT对主要终点远处转移(DM)的差异获益;在第七项随机试验RTOG 9202(N=1,192)中验证,该试验将男性随机分配至放疗+短期ADT(4个月)对比放疗+长期ADT(28个月)。

主要发现

  • 验证队列中位随访17.2年,长期ADT显著改善DM,从26%降至17%(sHR 0.64,95%CI 0.50-0.82,P<.001)。
  • MMAI生物标志物阳性男性(n=785,66%)长期ADT对比短期ADT降低DM(sHR 0.55,95%CI 0.41-0.73,P<.001)。
  • MMAI生物标志物阴性男性(n=407)未观察到治疗获益(sHR 1.06,95%CI 0.61-1.84,P=.84)。
  • 生物标志物与治疗对DM的预测交互作用显著(P=.04)。
  • 放疗+长期ADT对比放疗+短期ADT的估计15年DM风险差异在MMAI阳性男性中为14%,在MMAI阴性男性中为0%;MMAI生物标志物对DM也具有预后价值,无论治疗如何(sHR 2.35,95%CI 1.72-3.19,P<.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Long-term androgen deprivation therapy (ADT) improves survival in men with high-risk localized prostate cancer (PCa) receiving radiotherapy (RT). Predictive biomarkers are needed to guide ADT duration. METHODS: A multimodal artificial intelligence (MMAI)-derived predictive biomarker was trained for long-term (LT) versus short-term (ST) ADT using pretreatment digital prostate biopsy images and clinical data (age, prostate-specific antigen, Gleason, and T stage) from six NRG Oncology phase III randomized radiotherapy trials. The novel MMAI-derived biomarker was developed to predict the differential benefit of LT-ADT on the primary end point, distant metastasis (DM). MMAI predictive utility was validated on a seventh randomized trial, RTOG 9202 (N = 1,192), which randomly assigned men to RT + ST-ADT (4 months) versus RT + LT-ADT (28 months). Fine-Gray and cumulative incidence analyses for DM, and secondarily, death with DM, were performed. Deaths without DM were treated as competing risks. RESULTS: In the validation cohort (median follow-up, 17.2 years), LT-ADT significantly improved DM from 26% to 17% (subdistribution hazard ratio [sHR], 0.64 [95% CI, 0.50 to 0.82], P < .001). A significant biomarker-treatment predictive interaction was observed (P = .04) for DM, whereby MMAI biomarker-positive men (n = 785, 66%) had reduced DM with LT-ADT versus ST-ADT (sHR, 0.55 [95% CI, 0.41 to 0.73], P < .001), whereas no treatment benefit was observed for MMAI biomarker-negative men (n = 407; sHR, 1.06 [95% CI, 0.61 to 1.84], P = .84). The estimated 15-year DM risk difference between RT + LT-ADT and RT + ST-ADT was 14% in MMAI biomarker-positive men and 0% in MMAI biomarker-negative men. The MMAI biomarker was also prognostic for DM, irrespective of treatment (sHR, 2.35 [95% CI, 1.72 to 3.19], P < .001). CONCLUSION: To our knowledge, the MMAI model is the first validated predictive biomarker to guide ADT duration with RT in localized/locally advanced PCa. Approximately one third of men with high-risk PCa could safely be spared the additional 24 months of ADT and the associated morbidity.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Armstrong AJ, Liu VYT, Selvaraju RR, et al. Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials. J Clin Oncol. 2025. PMID: 40239134. doi:10.1200/JCO.24.00365

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。